Data showed that the primary endpoint of recurrence-free survival (RFS) met the pre-specified futility criteria
Receives 3 final and 2 tentative product approvals thus far in Q1FY25
If approved, the Opdivo-based regimen would be the first immunotherapy-chemotherapy combination approved for this patient population in the EU
If approved, enfortumab vedotin with KEYTRUDA would be the first combination in China to offer an alternative to chemotherapy
BioNTech's diverse pipeline includes multiple drugs in Phase I, II, and III clinical trials
Sun Pharma will have exclusive rights to commercialise Nidlegy for indications of skin cancers in the territories of Europe, Australia and New Zealand. Philogen will complete pivotal clinical trials for the product in Europe
mRNA-4157 (V940) in combination with KEYTRUDA reduced the risk of recurrence or death by 44% compared to KEYTRUDA alone in stage III/IV melanoma patients
Designation based on positive data from Phase 2b KEYNOTE-942/mRNA-4157-P201 trial and unmet need for additional therapeutic options for certain types of melanoma
Designation based on positive data from Phase 2b KEYNOTE-942/mRNA-4157-P201 trial
Moderna and Merck announced mRNA-4157/V940, in combination with KEYTRUDA, demonstrated a 44% reduction in the risk of disease recurrence or death in melanoma patients
Subscribe To Our Newsletter & Stay Updated
